MAPT and Alzheimer disease: In 3xTg-AD mice, Se treatment slightly decreases phosphorylated tau levels but even more significantly reduced total tau levels, as analyzed with two distinct antibodies (TG5 and 17025) (P < 0.05; Fig. 4B,C).